A novel three-dose regimen of daclizumab in liver transplant recipients with hepatitis C: A pharmacokinetic and pharmacodynamic study

Liver Transplantation

Volumn 12, Issue 4, 2006, Pages 585-591

  Washburn, W Kenneth ^a   Teperman, Lewis W ^b   Heffron, Thomas G ^c   Douglas, David D ^d   Gay, Steven ^e   Katz, Eliezer ^e   Klintmalm, Goran B G ^f  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MAYO CLINIC   (United States)

^e CTI Clinical Trial and Consulting Services   (United States)

^f BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DACLIZUMAB; INTERLEUKIN 2 RECEPTOR ALPHA; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TSUKUBAENOLIDE;

ADULT; AFRICAN AMERICAN; ARTICLE; ASIAN; BLOOD SAMPLING; CAUCASIAN; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GRAFT FAILURE; HEPATITIS C; HISPANIC; HUMAN; LEUKOPENIA; LIVER FAILURE; LIVER GRAFT REJECTION; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

ANTIBODIES, MONOCLONAL; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FLOW CYTOMETRY; HEMODYNAMIC PROCESSES; HEPATITIS C; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; SAFETY; TREATMENT OUTCOME;

EID: 33645538211     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.20631     Document Type: Article

References (21)

1. Goebel J, Stevens E, Forrest K, Roszman T. Daclizumab (Zenapax) inhibits early interleukin-2-receptor signal transduction events. Transpl Immunol 2000;8:153-159.
2. Berard J, Velez R, Freeman R, Tsunoda S. A review of interleukin-2 receptor antagonists in solid organ transplantation. Pharmacotherapy 1999:19:1127-1137.
3. Vincenti F, Kirkman R, Light S, Bumgardner G, Pescovitz M, Halloran P, et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 1998;338:161-165.
4. Pescovitz MD. Bumgardner G, Gaston RS, Kirkman R, Light S, Patel I, et al. Pharmacokinetics of Daclizumab and mycophenolate mofetil with cyclosporine and steroids in renal transplantation. Clin Transplant 2003; 17:511-517.
5. Daclizumab [package insert]. Nutley, New Jersey: Hoffman-La Roche, Inc.;2003.
6. Koch M, Niemeyer G, Patel I, Light S, Nashan B. Pharmacokinetics, pharmacodynamics, and immunodynamics of Daclizumab in a two-dose regimen in liver transplantation. Transplantation 2002,73:1640-1646.
7. Eckhoff D. McGuire B, Sellers M, Contreras J, Frenette L, Toung C, et al. The safety and efficacy of a two-dose Daclizumab (Daclizumab) induction therapy in liver transplant recipients. Transplantation 2000;69:1867-1872.
8. Emre S, Gondolesi G. Polat K, Ben-Haim M, Artis T, Fishbein T, et al. Use of Daclizumab as initial immunosuppression in liver transplant recipients with impaired renal function. Liver Transpl 200 1;7:220-225.
9. Innocenti F, Humeras F, Zamboni M. Sanhueza E, Zapata R, Hepp J, et al. IL-2 receptor blockers in liver transplantation: Initial experience with Daclizumab in Chile. Transplant Proc 2003;35:2520-2521.
10. Figueras J, Bernardos A, Prieto M, Gomez M, Rimola A, Ortiz de Urbina J, et al. Steroid-free regimen with daclizumab, mycophenolate mofetil, and tacrolimus in liver transplant recipients. Transplant Proc 2002;34:1511-1513.
11. Washburn K, Speeg KV, Esterl R. Cigarroa F, Pollack M, Tourtellot C, et al. Steroid elimination 24 hours after liver transplantation using Daclizumab, tacrolimus, and mycophenolate mofetil. Transplantation 2001;72:1675-1679.
12. Sheiner PA, Schwartz ME, Mor E, Schluger LK, Theise N. Kishikawa K, et al. Severe or multiple episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology 1995;21:30-34.
13. Fayer BE, Soni PP, Binger MH, Mould DR, Satoh H. Determination of humanized-anti-TAC in hurnan serum by a sandwich enzyme linked immunosorbent assay. J Immunol Methods 1995;186:47-54.
14. Nashan B, Light S, Hardie I, Lin A, Johnson JR. Reduction of acute renal allograft rejection by Daclizumab. Transplantation 1999;67:110-115.
15. Ciancio G, Burke G, Suzart K, Roth D. Kupin W, Rosen A, et al. Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients. Transplantation 2002;73:1100-1106.
16. Ciancio G. Mattiazzi A, Roth D. Kupin W, Miller J, Burker GW. The use of Daclizumab as induction therapy in combination with tacrolimus and mycophenolate mofetil in recipients with previous transplants. Clin Transplant 2003;17: 428-432.
17. Sarwal M, Yorgin P, Alexandqr S, Millan MT, Belson A, Belanger N, et al. Promising early outcomes with a novel, complete steroid avoidance immunosuppression protocol In pediatric renal transplantation. Transplantation 2001; 72:13-21.
18. Kuypers D, Evenepoel P, Maes B, Coosemans W, Pirenne J. Vanrenterghem Y. The use of an anti-CD25 monoclonal antibody and mycophenolate mofetil enables the use of a low-dose tacrolimus and early withdrawal of steroids in renal transplant recipients. Clin Transplant 2003; 17:234-41.
19. Eckberg H, Persson NH, Kallen R, Gul-Baykurt N. Two doses of Daclizumab in conjunction with low-dose cyclosporine, mycophenolate mofetil and steroids resulted in a low incidence of acute rejection after renal transplantation. Scand J Immunol. 2003;58:670-677.
20. Light JA, Sasaki TM, Ghasemian P. Barhyte DY, Fowlkes DL. Daclizumab induction/tacrolimus sparing: A randomized prospective trial in renal transplantation. Clin Transplant 2002; 16:30-33.
21. Vincenti F. Pace D. Birnbaum, Lantz M. Pharmacokinetic and pharmacodynamic studies of 1 or 2 doses of Daclizumab in renal transplantation. Am J Transplantation 2003:3:50-52.